Pharma R&D stands to benefit from well-deployed grids

Pharma R&D stands to benefit from well-deployed grids

With increased pressure on bottom lines and top lines pharma , companies must turn to IT for competitive edge. Grid computing will be the next big technology for R&D labs to reduce time to market, says Arun Gupta, Senior Director, Business Technology, Pfizer

IT in the pharma and biotech industry will facilitate new development, and improve time to market. The next big technology for the pharma industry is grid computing because R&D requires intensive processing power. Grid computing holds the promise for high through put screening of thousands of molecules per day. Thus increasing speed to market and using less resources in terms of  people and money.

Web-technologies within the organisation for operational information have already been deployed. Use of electronic filing of documents to FDA, clinical data capture, medical writing is just catching on. Clinical trials data gathering has been manual in the past. IT helps cuts cycle time tremendously in data entry, verification.

Change management continues to be the toughest problem faced by IT in the sector. Education, and continuing to convey value of IT is the only way out. Pharma has been conservative in adopting IT, because there has not been too much pressure. Now, with blockbusters reaching end of the patent cycles, there is increased pressure on both top line and bottom line.

We assess IT value based on three parameters—impact on top line and bottom line, and new capabilities offered. A recent addition, with new regulations such as SOX on the scene, is regulatory compliance and facilitation of documentation.